Edwards Lifesciences Corp [NYSE: EW] traded at a high on Friday, posting a 9.38 gain after which it closed the day’ session at $86.09. The company report on February 2, 2024 at 7:00 AM that Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve.
Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.
“Edwards has a long history of leading innovation and pioneering new therapies to address the unmet needs of patients with structural heart disease,” said Daveen Chopra, Edwards’ corporate vice president, transcatheter mitral and tricuspid therapies. “We are grateful for the strong collaboration with clinicians all over the world who contributed to the EVOQUE system now being available through FDA’s Breakthrough Pathway to provide a treatment option to the many patients in the US suffering with tricuspid valve disease.”.
The results of the trading session contributed to over 11734825 shares changing hands. Over the past one week, the price volatility of Edwards Lifesciences Corp stands at 3.61% while the volatility over the past one month is 2.60%.
The market cap for EW stock reached $52.21 billion, with 608.30 million shares outstanding and 596.89 million shares in the current float. Compared to the average trading volume of 4.22M shares, EW reached a trading volume of 11734825 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Edwards Lifesciences Corp [EW]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $80.49 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.09. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Edwards Lifesciences Corp shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on February 02, 2024.
The Average True Range (ATR) for Edwards Lifesciences Corp is set at 2.37, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 8.97. The Price to Book ratio for the last quarter was 7.84, with the Price to Cash per share for the same quarter was set at 3.07. Price to Free Cash Flow for EW in the course of the last twelve months was 64.59 with Quick ratio for the last quarter at 2.45.
How has EW stock performed recently?
Edwards Lifesciences Corp [EW] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.55. With this latest performance, EW shares gained by 17.72% in over the last four-week period, additionally plugging by 7.61% over the last 6 months – not to mention a rise of 5.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 77.42, with the RSI for the last a single of trading hit 83.35, and the three-weeks RSI is set at 72.94 for Edwards Lifesciences Corp [EW]. The present Moving Average for the last 50 days of trading for this stock 73.34, while it was recorded at 78.35 for the last single week of trading, and 78.23 for the last 200 days.
Edwards Lifesciences Corp [EW]: Deeper insight into the fundamentals
Edwards Lifesciences Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.45 and a Current Ratio set at 3.28.
Earnings analysis for Edwards Lifesciences Corp [EW]
With the latest financial reports released by the company, Edwards Lifesciences Corp posted 0.64/share EPS, while the average EPS was predicted by analysts to be reported at 0.61/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corp go to 7.99%.
Insider trade positions for Edwards Lifesciences Corp [EW]
The top three institutional holders of EW stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in EW stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in EW stock with ownership which is approximately 5.8325%.
